Achalasia Treatment Market By Treatment Type (Drug Therapy, Endoscopic Therapy, Surgical Therapy, Lifestyle Modifications); By Diagnosis Type (Esophageal Manometry, Endoscopy, Imaging Barium Swallow Test); By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

What Is the Current Achalasia Treatment Market Size and How Is the Treatment Landscape Evolving?

The Global Achalasia Treatment Market was valued at USD 618.40 million in 2025 and is projected to reach USD 1.02 billion by 2032, expanding at a CAGR of 7.43% during 2026–2032, according to Strategic Market Research.

 

The achalasia treatment market includes the medical procedures and medicines used to help patients with achalasia, a condition in which the lower esophageal sphincter does not relax properly and the esophagus cannot move food effectively into the stomach.  Key companies include Boston Scientific, which provides pneumatic dilation balloons and endoscopic devices; Olympus, whose endoscopy platforms and accessories support POEM and related interventions; and Erbe Elektromedizin, whose electrosurgical systems support endoscopic tissue dissection and hemostasis during POEM. 

 

The achalasia treatment market is driven by a growing number of diagnosed patients and increasing use of advanced procedures. Worldwide, achalasia affects approximately 10.82 people per 100,000, with about 0.78 new cases per 100,000 people each year. Although the condition can occur at any age, it is most common in adults, particularly those between 30 and 60 years old.In the United States, prevalence is estimated at 18.0 cases per 100,000 commercially insured individuals and 162.1 cases per 100,000 Medicare beneficiaries. The higher rate among Medicare patients reflects the greater burden in older adults.

 

Achalasia Treatment Market Segment Leaders and Emerging Growth Areas

Segments: Treatment Type

• Leading & Fastest-Growing – Endoscopic Therapy: Endoscopic therapy led with a 43.0% share, worth USD 265.91 million in 2025, and is projected to grow at the fastest CAGR of 9.2%, supported by expanding POEM adoption and continued use of pneumatic dilation.

 

Segments: Diagnosis Type

• Leading & Fastest-Growing – Esophageal Manometry: Esophageal manometry accounted for 49.0% of the segment, valued at USD 303.02 million in 2025, and is projected to grow at the fastest CAGR of 8.0%, supported by its central role in confirming achalasia and identifying disease subtypes.

 

Segments: End User

• Leading – Hospitals: Hospitals held the largest share at 52.0%, representing USD 321.57 million in 2025, supported by advanced endoscopy, surgical capabilities and multidisciplinary management of complex cases.

• Fastest-Growing – Ambulatory Surgical Centers: Ambulatory surgical centers accounted for 18.0%, or USD 111.31 million in 2025, and are projected to grow at the fastest CAGR of 9.1%, supported by expanding outpatient advanced-endoscopy capabilities.

 

Segments: Geography

• Leading – North America: North America led with a 38.0% share, valued at USD 234.99 million in 2025, supported by established motility centers, advanced endoscopy programs and broad access to specialist treatment.

• Fastest-Growing – Asia-Pacific: Asia-Pacific represented 23.0%, or USD 142.23 million in 2025, and is projected to grow at the fastest CAGR of 9.4%, supported by expanding POEM expertise and advanced gastrointestinal endoscopy capacity.

 

Treatment Modalities Driving Growth Across the Achalasia Treatment Market

Drug therapy represented a smaller share of the achalasia treatment market, accounting for 20.0% of total revenue, equivalent to USD 123.68 million in 2025. Although it is projected to grow at a CAGR of 4.8% from 2026 to 2032, its clinical role remains limited. Drug-based treatments are generally used for temporary symptom relief or in patients unsuitable for invasive procedures, as they provide lower effectiveness and are associated with more side effects compared with endoscopic interventions or surgical approaches.

Endoscopic therapy dominated the treatment segment, accounting for the largest market share of 43.0%, valued at USD 265.91 million in 2025. The segment is projected to grow at a CAGR of 9.2% during the forecast period, driven by increasing adoption of minimally invasive procedures. This therapy focuses on reducing the tightness of the lower esophageal sphincter (LES) muscle, improving its ability to relax and enabling smoother passage of food and liquids into the stomach, thereby relieving swallowing difficulties.

Surgical therapy accounted for 31.0% of the achalasia treatment market, reaching USD 191.70 million in 2025, and is expected to expand at a CAGR of 6.5%. It remains the preferred treatment approach due to its ability to provide long-term relief from swallowing difficulties (dysphagia). By surgically cutting the tight lower esophageal sphincter muscle, the procedure improves the passage of food into the stomach, enhancing patient outcomes and quality of life.

Lifestyle modifications accounted for 6.0% of the market, representing USD 37.10 million in 2025, with a projected CAGR of 5.2%. Nutritional counseling, smaller meals, eating-position changes and reflux management are mainly used alongside procedural care. This segment remains commercially smaller because such interventions do not correct impaired lower-esophageal-sphincter relaxation and therefore cannot replace definitive treatment in symptomatic patients.

 

Diagnostic Technologies Redefining the Achalasia Treatment Pathway

Esophageal manometry held 49.0% of the diagnosis-type market, representing USD 303.02 million in 2025, and is projected to expand at an 8.0% CAGR. High-resolution manometry is commercially important because treatment choice now depends increasingly on identifying Type I, Type II or Type III achalasia rather than confirming the disorder alone. CMS coverage guidance for POEM specifically identifies high-resolution manometry as part of the pretreatment assessment, strengthening the link between diagnostic utilization and definitive procedure selection.

Endoscopy accounted for 31.0%, or USD 191.70 million in 2025, and is expected to grow at a CAGR of 6.7%. It serves two commercial roles: excluding mechanical obstruction or malignancy that can mimic achalasia and providing the platform for POEM, pneumatic dilation and botulinum toxin injection. As more gastroenterology departments establish third-space endoscopy programs, the same installed endoscopic equipment can support diagnosis and intervention, improving utilization of existing advanced-GI infrastructure.

Imaging through barium swallow testing represented 20.0% of the segment, equivalent to USD 123.68 million in 2025, and is projected to expand at a 7.1% CAGR. Timed barium esophagrams quantify retained contrast and esophageal emptying and are particularly useful when symptoms and manometry findings require additional functional context. Their continued role in pretreatment assessment and post-treatment evaluation prevents imaging from being displaced by manometry despite the latter's greater diagnostic specificity.

Functional-lumen imaging is also broadening the diagnostic ecosystem without replacing the supplied segmentation categories. Medtronic's EndoFLIP 300 measures esophageal dimensions and pressure and provides real-time information about gastroesophageal-junction opening dynamics. The system is positioned as an adjunct to other diagnostic methods rather than a standalone replacement for high-resolution manometry.

 

Care-Setting Shifts Reshaping the Achalasia Treatment Market

Hospitals held 52.0% of the Achalasia Treatment Market in 2025, representing USD 321.57 million, and are projected to grow at a CAGR of 6.8%. Their leadership reflects the concentration of POEM, LHM and complicated pneumatic dilation cases in institutions with advanced endoscopy, foregut surgery, anesthesia and emergency surgical support. CMS coverage guidance similarly describes POEM as a complex procedure appropriate for adequately trained physicians in high-volume centers able to manage GI or cardiothoracic complications.

Specialty clinics represented 30.0% of the market, equivalent to USD 185.52 million in 2025, and are forecast to grow at an 8.2% CAGR. Dedicated gastroenterology, esophageal-motility and foregut clinics increasingly coordinate high-resolution manometry, endoscopy, treatment selection and long-term reflux or recurrence assessment. Their commercial role is strongest where treatment itself occurs at an affiliated hospital but diagnosis, patient selection and follow-up remain within specialist outpatient programs.

Ambulatory surgical centers (ASCs) accounted for 18.0% of the market, valued at USD 111.31 million in 2025, and are anticipated to experience the fastest growth among end users, with a CAGR of 9.1%. ASCs offer convenient outpatient care environments that support minimally invasive achalasia treatments, including pneumatic dilation and selected diagnostic endoscopic procedures

 

Regional Growth Frontiers Accelerating POEM Adoption in the Achalasia Treatment Market

North America dominated the Achalasia Treatment Market in 2025, accounting for 38.0% of the global share, valued at USD 234.99 million, and is expected to grow at a CAGR of 6.6%. The region has witnessed a significant shift from conventional surgical procedures toward minimally invasive endoscopic techniques, driven by improved clinical outcomes, shorter recovery times, and increasing adoption of advanced treatments such as peroral endoscopic myotomy (POEM).

Europe accounted for 28.0% of the market share in 2025, valued at USD 173.15 million, and is projected to expand at a CAGR of 7.0% during the forecast period. The region is experiencing a significant shift toward minimally invasive endoscopic and surgical approaches, driven by the increasing adoption of advanced procedures such as Per-oral Endoscopic Myotomy (POEM) and Laparoscopic Heller Myotomy (LHM).

Asia-Pacific region is emerging as the fastest-growing market, accounting for 23.0% of the global share, valued at USD 142.23 million in 2025. The region is projected to achieve the highest CAGR of 9.4% during the forecast period, driven by increasing adoption of advanced and minimally invasive therapies. Rising healthcare investments, improving medical infrastructure, and growing demand for innovative treatment solutions are accelerating market expansion across key Asia-Pacific countries.

Latin America accounted for 7.0% of the market, valued at USD 43.29 million in 2025, and is expected to grow at an 8.0% CAGR during the forecast period. The region is witnessing a gradual shift from conventional open surgeries toward advanced minimally invasive interventions, driven by improving healthcare infrastructure, rising adoption of innovative technologies, and the need for effective treatment solutions for region-specific health challenges, including Chagas disease.

Middle East & Africa (MEA) region accounted for 4.0% of the market, valued at USD 24.74 million in 2025, and is projected to expand at a CAGR of 7.7%. The region presents a diverse healthcare landscape, characterized by a significant contrast between rapidly developing medical hubs equipped with advanced technologies and resource-constrained areas facing limited access to healthcare infrastructure.

 

 Competitive Forces and Leading Companies in the Achalasia Treatment Market

Competition in the Achalasia Treatment Market is distributed across pneumatic-dilation balloons, impedance planimetry, endoscopic knives, electrosurgical platforms and other advanced-endoscopy tools rather than being controlled by one pharmaceutical franchise. Competitive positioning therefore depends on procedure compatibility, physician familiarity, workflow efficiency, diagnostic integration and the breadth of equipment that can participate across the achalasia care pathway.

Boston Scientific

Boston Scientific participates directly through the RIGIFLEX II Single-Use Achalasia Balloon Dilator portfolio. The system is available in 30 mm, 35 mm and 40 mm balloon sizes, matching the graduated dilation approach commonly used in pneumatic dilation. The original RIGIFLEX single-use achalasia balloon received FDA 510(k) clearance specifically as an esophageal dilator balloon.

Its position remains tied to the continued clinical relevance of pneumatic dilation. Repeat dilation requirements create recurring procedure utilization, while the availability of several balloon diameters allows clinicians to escalate treatment according to patient response rather than moving immediately to myotomy.

Medtronic

Medtronic participates through the EndoFLIP 300 impedance planimetry platform and EsoFLIP dilation portfolio. EndoFLIP measures pressure and dimensions across the gastroesophageal junction, providing functional information that can support assessment before, during or after myotomy. EsoFLIP ES-330 combines controlled dilation with real-time diameter measurement and is specifically indicated for dilation of the gastroesophageal junction in patients with achalasia.

The portfolio gives Medtronic exposure to both diagnostic assessment and intervention rather than only one procedure type. FDA's August 2026 Class II recall concerns the older EF-100 EndoFLIP System and its catheter-recognition software issue; the FDA notice identifies use of the EF-300 system as an available alternative where present.

Olympus Corporation

Olympus is positioned within the POEM workflow through its endoscopy and endotherapy portfolio. Relevant products include DualKnife J, HookKnife J, TriangleTipKnife J and ITKnife Nano, which support mucosal entry, submucosal dissection and myotomy. Olympus also maintains dedicated POEM and ESD education around these devices, making physician training an important part of its competitive position in advanced endoscopy.

As hospitals add POEM capability, Olympus can participate through equipment already used across other complex endoscopic procedures, allowing achalasia treatment to fit into a broader advanced-GI platform rather than requiring an entirely separate capital system.

ERBE Elektromedizin

ERBE competes through electrosurgical and hydrosurgical equipment used during POEM. Its relevant portfolio includes HybridKnife, VIO electrosurgical platforms and ERBEJET technology. HybridKnife combines fluid-assisted tissue elevation with electrosurgical cutting and coagulation, reducing instrument exchanges during creation of the submucosal tunnel and myotomy.

This workflow-based positioning becomes commercially relevant as POEM programs mature and providers focus not only on procedural success but also on instrument changes, bleeding control and procedure efficiency.

Cook Medical

Cook Medical participates in pneumatic dilation through the Wilson-Cook Achalasia Balloon. FDA 510(k) documentation identifies the Class II device for dilation of the lower esophageal sphincter in adults with achalasia, with 30 mm and 35 mm balloon configurations.

Its presence creates direct product competition in the achalasia-balloon category and reinforces the continuing commercial viability of pneumatic dilation even as POEM captures a larger share of definitive interventions.

 

Analyst Commentary: Precision POEM and Functional Imaging Set the Next Breakthrough Frontier

The most likely breakthrough in achalasia treatment through 2032 will come from advanced endoscopic procedures rather than new medicines. POEM is expected to gain further preference because of its minimally invasive approach and effectiveness across achalasia subtypes, particularly Type III disease. The next evolution could be POEM combined with endoscopic fundoplication (POEM-F), which aims to preserve POEM's treatment effectiveness while reducing its major limitation—post-procedure gastroesophageal reflux. If ongoing clinical studies demonstrate durable reflux control, POEM-F could become an important alternative to conventional POEM and laparoscopic Heller myotomy.

A second major innovation area is FLIP-guided personalized myotomy. Functional lumen imaging can measure gastroesophageal-junction distensibility during treatment, enabling physicians to determine whether sufficient muscle division has been achieved in real time. This could shift achalasia therapy from standardized procedural techniques toward physiology-guided treatment, potentially improving outcomes while avoiding unnecessarily extensive myotomy. AI-supported interpretation of high-resolution manometry and endoscopic images could further accelerate diagnosis and improve patient selection for specific procedures.

A pharmaceutical breakthrough appears less likely in the near term. Current drugs, including nitrates, calcium-channel blockers and botulinum toxin, mainly provide temporary symptom relief rather than addressing the underlying loss of inhibitory esophageal neurons. A truly disruptive medicine would need to restore or regenerate enteric neuronal function, effectively modifying the disease instead of relaxing the sphincter temporarily. Such therapies remain experimental, making reflux-controlled POEM, functional imaging and AI-assisted diagnostics the most commercially realistic breakthrough opportunities during the forecast period.

 

Achalasia Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 618.40 Million
Revenue Forecast in 2032	USD 1.02 Billion
Overall Growth Rate	CAGR of 7.43% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million/Billion, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Diagnosis Type, By End User, By Geography
By Treatment Type	Drug Therapy, Endoscopic Therapy, Surgical Therapy, Lifestyle Modifications
By Diagnosis Type	Esophageal Manometry, Endoscopy, Imaging Barium Swallow Test
By End User	Hospitals, Specialty Clinics, Ambulatory Surgical Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Growing number of diagnosed patients, increasing use of advanced procedures, expanding POEM adoption, continued use of pneumatic dilation, high-resolution manometry, functional-lumen imaging, and expanding outpatient advanced-endoscopy capabilities
Customization Option	Available upon request